925 Fuji have 90 days from when the independent assessment board approve to go ahead to phase 2. This will happen after 100 days of last patient so Fuji under no pressure to take up the option for at least 5 months yet.
The question will likely be if someone else takes up a licensing agreement with us for another indication in the meantime. That will put Fuji under pressure to make some quick decisions otherwise until then they have plenty of time.
My gut feeling is that there are cogs turning behind the scenes to get another company on board for another indication (the company has mentioned CLI as being their next target)
We sit and wait or sell and try to get back in after a big news announcement.
I'll sit it out !
GLTAH DYOR
CYP Price at posting:
$1.18 Sentiment: Buy Disclosure: Held
